Covid-19 Vaccination in Patients with Inflammatory Bowel Diseases

Covid-19 Vaccination in Patients with Inflammatory Bowel Diseases - CoVac IBD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025694

Enrollment

Registered

2021-06-22

Start date

2021-06-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Interventions

Group 1: Sequential evaluation of Covid-19 vaccination response at different time points

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: - Male and female patients aged =18 years - History of inflammatory bowel disease (>3 months) - IBD patients prior to Covid-19 vaccination - Written informed consent from the patient

Exclusion criteria

Exclusion criteria: - Conditions that do not allow the subject to appreciate the nature, scope, and possible consequences of the clinical trial. - Indications that the patient is unlikely to comply with the protocol (e.g., unwillingness to cooperate) - Covid-19 vaccination already administered.

Design outcomes

Primary

Measure	Time frame
Characterization of the cellular and humoral immune response after Covid-19 vaccination in IBD (Inflammatory Bowel Diseases) patients.	—

Secondary

Measure	Time frame
Differentiation of the immune response after Covid-19 vaccination under different immunosuppressive therapies in IBD patients. Evaluation of the influence if Covid-19 vaccination on IBD disease progression. Evaluation of negative predictive factors on vaccination response after Covid-19 vaccination in IBD patients.	—

Countries

Germany

Contacts

Public ContactMiriam Wiestler

Medizinische Hochschule Hannover

wiestler.miriam@mh-hannover.de0511-532-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026